Medicover first in Europe to launch pilot project aimed at identifying patients at risk of colorectal cancer

Medicover first in Europe to launch pilot project aimed at identifying patients at risk of colorectal cancer


Medicover Polska is testing the ColonFlag modern solution that will allow to effectively identify patients at risk for colorectal cancer. The tool determines the risk of intestinal lesions by further analysing the results of a commonly performed blood test. The pilot project is being developed in collaboration with Medial EarlySign, an Israeli company that creates machine-learning systems in the area of data-driven medicine.

ColonFlag is a solution that identifies patients who may experience gastrointestinal microbleeding caused by polyps or cancer. A positive result is an indication for colonoscopy.

ColonFlag helps make diagnostic decisions thanks to applying advanced AI algorithms to data from frequently performed laboratory tests. The programme analyses data such as the results of a CBC test and other data contained in electronic medical records.

- Dr Piotr Soszyński, Director of Medical Systems at Medicover Polska

This makes it possible for the tool to identify people who are in a high risk group and require further testing.

Colon cancer is the second most common cancer in women in Poland and the third among males. It is the fourth most common cause of death due to cancer. In Poland, the average survival rate after five years is slightly below 50%. If colorectal cancer is diagnosed at an early stage, the rate may even exceed 90%. Early detection has enormous importance for the successful treatment of colorectal cancer. ColonFlag can help us better identify patients in the high risk group. Thanks to this, referrals for colonoscopy may result in a better chance of detecting the disease and significantly improve the outcome of treatment.

- Dr Bożena Walewska-Zielecka, Medical Director at Medicover Polska

The success of the project may mean that Medicover Polska will begin using the ColonFlag tool in routine diagnostic procedures.

We are pleased to be working with Medicover on their first use of machine-learning algorithms to streamline the processes of diagnostic decision making. This is the first step towards integrating technology that will have a far-reaching impact on the work of doctors and medical service providers. It will give them tools to provide individualised care for patients in the high risk group. - Ori Geva, CEO of Medial EarlySign.
The pilot programme using the innovative method is being implemented at Medicover Centres in Warsaw and in the south of Poland. The single analysis is performed in Medicover patients between the ages of 50 and 75 who have had a complete blood count test performed for any reasons and agreed to participate in the project. Medial EarlySign is currently conducting clinical trials in more than 20 million patients in 14 institutions around the world.

Copy as a Plain Text


Related Stories
Iwona Pokwicka is the new Vice President of the Board of Medicover sp. z o.o and Director of Operations for our Clinic Business


In January, Iwona Pokwicka was appointed Vice President of Medicover sp. z o.o. and Director of Operations in Medicover’s clinic business. In this position, she will be responsible for the functioning of Medicover medical clinics throughout Poland.
Leading orthopaedic clinic Rehasport at the Medicover Hospital


Professional medical help for injuries, accidents and contusions, comprehensive treatment and rehabilitation under the supervision of outstanding specialists who on a daily basis ensure the fitness of the biggest sport stars – available for patients at the Medicover Hospital in Warsaw’s Wilanów. The Rehasport Clinic, liaised with Medicover, is one of the four leading centres in Poland specializing in orthopaedics, rehabilitation and sports medicine. Professionalism and high quality are confirmed by international awards and the trust of many outstanding athletes.
E-health is much more than online prescriptions


From digital self-care through virtual doctor appointments to remote examinations. E-health offers a wide range of possibilities. According to experts, the Internet and telemedicine can be used at any stage of treatment – technology is not a barrier these days. However, how do we develop the potential of remote solutions in order for them to be effective, useful and safe for the patient? What is the priority for medical service providers today? What changes can we expect in the coming years?
Protect yourself against cancer – take a genetic predisposition test!


Over the next few years, cancer will become number one cause of death in our country. At present, nearly 157,000 Poles are diagnosed with malignant tumours every year and approximately 95,000 of them die. But contemporary medicine makes it possible to detect genes which may increase the risk of cancer development. Genetic predisposition tests are available, for instance, in the Medicover Medical Centre at Aleje Jerozolimskie 96.

Healthy baby - the challenge of modern times

In 2016, over 382,000 births were recorded in Poland [1]. Research shows that two thirds of parents feed their children the wrong diet and expand their children’s diet too quickly [2]. The knowledge on how to take proper care of infants is still insufficient, which increases the risk of disease in later years. That is why regular medical check-ups for a newborn baby are so important to ensure that his health and development are constantly assessed. Constant paediatric care also enables parents to deepen their knowledge about the best ways to take care of their child's health.